natera™ | Empower™
Hereditary cancer test

Meaningful insights, within reach.

High-quality hereditary cancer testing made accessible

Talk about hereditary cancer risk with your patients

Inherited mutations can significantly increase lifetime risk for developing cancer[1]



Many high risk patients are not tested

~85%

of women with a history of breast or ovarian cancer who meet NCCN criteria for genetic testing have not been tested[2]

~69%

of individuals at risk for Lynch syndrome were never advised by their health care provider to undergo genetic testing[3]

A central role for healthcare providers

> *"Evaluating a patient's risk of hereditary breast and ovarian cancer should be a routine part of obstetric and gynecologic practice"*
>
> **AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS PRACTICE BULLETIN 182 2017 (REAFFIRMED 2019)[4]**

Introducing Empower™

High-quality hereditary cancer testing made accessible

1 **Advanced technology**
Next generation sequencing used to analyze up to 53 genes associated with an increased risk for common hereditary cancers.

2 **Clear answers you can act on**
Reports include detailed patient management recommendations based on the latest medical guidelines including Tyrer-Cuzick assessments.

3 **Commitment to affordability**
In-network with a majority of insurance plans, and comprehensive programs to ensure patient access to testing.

4 **Practice support**
Services to simplify testing workflow at every step, including streamlined patient education, ordering and sample collection, billing, counseling and documentation.

From Natera, the experienced leader in genetic testing

3M+	100+	CAP	CLIA	90	50+
tests performed	clinicians, PhD's, and scientists	accredited	certified	countries worldwide	peer-reviewed publications

Hereditary cancer testing simplified

Designed with your practice in mind

Empower panels include genes associated with increased risk of common hereditary cancers, with options to suit your preferred screening strategy.



PANEL

BRCA1 & BRCA2

2 total genes

BRCA1 & BRCA2

Genes
BRCA1, BRCA2

PANEL

GYN guidelines-based

19 total genes

Breast, Ovarian, Endometrial cancers and Lynch Syndrome genes

Additional Genes
ATM, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53

PANEL

Multi-cancer*

40 total genes

Most commonly screened-for hereditary cancer genes across 8 cancer types

Additional Genes
APC, AXIN2, BAP1, BARD1, BMPR1A, CDK4, CDKN2A, GALNT12, GREM1, HOXB13, MEN1, MITF, MSH3, MUTYH, NTHL1, POLD1, POLE, RNF43, RPS20, SMAD4, VHL

PANEL

Multi-cancer expanded

53 total genes

Includes multi-cancer panel plus additional genes with emerging evidence of elevated cancer risks

Additional Genes
CTNNA1, DICER1, KIT, MRE11, PDGFRA, RAD50, SDHA, SDHB, SDHC, SDHD, SMARCA4, TSC1, TSC2

*Breast STAT panel available with 11 breast cancer genes reported within 5-7 calendar days + 29 additional genes reported within 2 weeks. Breast STAT genes include ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NBN, PALB2, PTEN, STK11 and TP53.

Vital testing made affordable

Broad, in network coverage

In-network provider with most health plans, including Anthem, Cigna,and UnitedHealthcare.

Check out our growing list at: **natera.com/in-network-plans**

Price transparency

Personalized estimates help patients understand coverage and cost—so you can focus on care.

Comprehensive patient access solutions

Self-pay pricing and compassionate care options are available for patients without adequate insurance coverage.

Family testing program

Testing for first-degree relatives of patients with a positive result at no additional charge.

Visit **natera.com/Empower** for more details

Actionable reports to guide patient management, including:

- Screenings that detect cancer at its earliest, most treatable stage
- Surgical or therapeutic decisions for patients diagnosed with cancer
- Risk-reducing surgical or therapeutic decisions for patients at elevated risk of developing cancer
- Informing family members to help them proactively manage hereditary cancer risk



Cancer Risk Estimates for *BRCA2*

Cancer risk estimates for a positive result are typically based on individuals with a family or personal history of cancer. Your risk may be different if you do not have a personal or family history of cancer.

Female	Cancer type	General Population - Estimated Lifetime Cancer Risk*	Positive Result - Estimated Lifetime Cancer Risk**
♀	Breast	12.80%	Up to 84% risk
	Ovarian	1.3%	Up to 27% risk
	Pancreatic	1.60%	2-7%
	Melanoma	1.80%	Increased

Risk Management and Screening Guidelines for Hereditary Breast and Ovarian Cancer Syndrome *

The following information is a summary of current US guidelines. Please discuss with your healthcare provider as screening recommendations may vary by country and can change often.

Cancer type	Mode of Screening or Risk Reduction	Typical Age to Begin	How often
Female Breast	Breast self-exam	18	Monthly
	Breast exam with clinician	25	Every 6-12 months
	Breast MRI with contrast	25-29 or individualized if family history of breast cancer below age 30	Annually
	Mammogram with consideration of tomosynthesis (3-D Mammogram)	30	Annually
	Risk-reducing medication	Individualized	Discuss with your healthcare provider
	Risk-reducing breast surgery (mastectomy); discuss with your healthcare provider	Individualized; a consideration for those with a personal and/or family history of breast cancer	N/A
Male Breast	Breast self-exam	35	Monthly
	Breast exam with clinician	35	Annually

Report supplements include detailed patient management recommendations based on medical guidelines

Delivered with clinical rigor

Expert variant interpretation

An experienced team of scientists, physicians and genetic counselors rigorously classifies variants according to American College of Medical Genetics (ACMG) guidelines

Sharing knowledge

Baylor Genetics regularly contributes clinically significant variants to ClinVar public database for the benefit of patients and the medical community

DEVELOPED IN PARTNERSHIP WITH

BAYLOR GENETICS

>4 **million** clinical tests performed

+

>40 **years** of experience

NateraCore—simple, tailored resources to support you and your patients every step of the way

Education
Patient-friendly materials and information sessions, covering basic genetics to specific tests

Access
Programs and price transparency – rooted in our commitment to provide affordable testing for all who can benefit

Ordering
Flexible options based around your needs, including intuitive remote ordering and comprehensive EMR solutions

Results
Clear, actionable reports, served with time-saving tools and a side of expert guidance

Next steps
Value-add services that go beyond the test to address what's next

A selection of our NateraCore offerings

Pre- and post-test genetic information sessions – access to board-certified genetic counselors, available to all providers and patients

Price Transparency Program (PTP) – personalized cost estimates and an affordable self-pay cash option

Virtual Testing – fully remote testing option, combining online ordering with self-service patient education and mobile phlebotomy

Flexible phlebotomy options – via local, Natera-approved lab or at-home mobile services; available in all states, at no cost to patients

Compassionate Care – ensuring access to affordable testing for patients experiencing financial hardship

NateraSync EMR solutions – flexible solution suite to enable ordering and results delivery directly in your EMR

References

1 Cancer risk estimates for a positive result are typically based on individuals with a family or personal history of cancer.
NCCN Clinical Practice Guidelines in Oncology Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic v2.2021

2 Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer. JCO. 2017 Dec 1; 35:3800-38063.

3 Patel SG, Ahnen DJ, Kinney AY, et al. Am J Gastroenterol. Knowledge and uptake of genetic counseling and colonoscopic screening among individuals at increased risk for lynch syndrome and their endoscopists from the family health promotion project. 2016 Feb;111(2):285-93.

4 Modesitt SC, Lu K, Chen L and Powell CB. Obstet Gynecol. Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. 2017 Sep;130(3):e110-e126. (Reaffirmed 2019)

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com

EMP_BR_HCP_Oncology_20210608_NAT-8020080

natera™